A:NYE-Agilent Technologies Inc. (USD)

EQUITY | Diagnostics & Research | New York Stock Exchange

Last Closing

USD 145.51

Change

-1.86 (-1.26)%

Market Cap

USD 14.27B

Volume

2.18M

Analyst Target

USD 102.38
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Agilent Technologies Inc provides application focused solutions that includes instruments, software, services and consumables for the entire laboratory workflow for life sciences, diagnostics and applied chemical markets.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-03-28 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
TMO Thermo Fisher Scientific Inc

N/A

USD 220.96B
DHR Danaher Corporation

N/A

USD 182.08B
IQV IQVIA Holdings Inc

N/A

USD 45.94B
MTD Mettler-Toledo International I..

N/A

USD 27.82B
WAT Waters Corporation

N/A

USD 19.89B
LH Laboratory Corporation of Amer..

N/A

USD 17.77B
DGX Quest Diagnostics Incorporated

N/A

USD 14.27B
CRL Charles River Laboratories

N/A

USD 13.04B
RVTY Revvity Inc.

N/A

USD 12.54B
QGEN Qiagen NV

N/A

USD 9.22B

ETFs Containing A

TECX:CA TD Global Technology Lead.. 100.34 % 0.00 %

N/A

CAD 2.43M
HHL-U:CA Harvest Healthcare Leader.. 5.25 % 0.00 %

N/A

N/A
HHL-B:CA Harvest Healthcare Leader.. 5.25 % 0.00 %

N/A

N/A
EDOC Global X Telemedicine & D.. 5.23 % 0.00 %

N/A

USD 0.05B
EDOC:LSE Global X Telemedicine & D.. 5.18 % 0.00 %

N/A

USD 5.32M
EDOG:LSE Global X Telemedicine & D.. 5.18 % 0.00 %

N/A

USD 5.32M
GNOM Global X Genomics & Biote.. 4.89 % 0.00 %

N/A

USD 0.09B
DDOC:F Global X Telemedicine & D.. 4.63 % 0.00 %

N/A

USD 5.32M
EDOC:SW Global X Telemedicine & D.. 4.63 % 0.00 %

N/A

USD 4.92M
GNOG:LSE Global X Genomics & Biote.. 4.57 % 0.00 %

N/A

USD 8.88M
GN0M:XETRA Global X Genomics & Biote.. 4.47 % 0.00 %

N/A

USD 7.05M
GNOM:SW Global X Genomics & Biote.. 3.93 % 0.00 %

N/A

USD 6.73M
ABIE:XETRA AXA IM ACT Biodiversity E.. 2.41 % 0.00 %

N/A

N/A
ABIT:XETRA AXA IM ACT Biodiversity E.. 2.29 % 0.00 %

N/A

USD 0.41B
ABIT:F AXA IM ACT Biodiversity E.. 2.29 % 0.00 %

N/A

N/A
ABIE:F AXA IM ACT Biodiversity E.. 2.29 % 0.00 %

N/A

N/A
HIG:CA Global Healthcare Income .. 0.00 % 1.02 %

N/A

CAD 0.05B
GOAT 0.00 % 0.00 %

N/A

N/A
HHL:CA Harvest Healthcare Leader.. 0.00 % 1.15 %

N/A

CAD 0.33B
DRDR:LSE iShares Healthcare Innova.. 0.00 % 0.00 %

N/A

USD 1.14B
2B78:XETRA iShares Healthcare Innova.. 0.00 % 0.00 %

N/A

USD 1.14B
MJJ 0.00 % 0.00 %

N/A

N/A
MJO 0.00 % 0.00 %

N/A

N/A
DDOC:XETRA Global X Telemedicine & D.. 0.00 % 0.00 %

N/A

USD 5.32M
2B78:F iShares Healthcare Innova.. 0.00 % 0.00 %

N/A

N/A
XGEN:XETRA Xtrackers MSCI Genomic He.. 0.00 % 0.00 %

N/A

USD 3.51M

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 4.66% 47% F 55% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.66% 47% F 52% F
Trailing 12 Months  
Capital Gain 8.19% 77% C+ 50% F
Dividend Return 0.68% 43% F 7% C-
Total Return 8.87% 69% C- 42% F
Trailing 5 Years  
Capital Gain 81.03% 64% D 81% B-
Dividend Return 4.93% 80% B- 17% F
Total Return 85.96% 73% C 79% B-
Average Annual (5 Year Horizon)  
Capital Gain 16.81% 75% C 82% B
Dividend Return 17.53% 75% C 81% B-
Total Return 0.73% 83% B 19% F
Risk Return Profile  
Volatility (Standard Deviation) 30.08% 50% F 37% F
Risk Adjusted Return 58.28% 75% C 84% B
Market Capitalization 14.27B 79% B- 94% A

Key Financial Ratios

  Ratio vs. Industry/Classification (Diagnostics & Research) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 31.90 54% 19%
Price/Book Ratio 6.98 36% 12%
Price / Cash Flow Ratio 24.37 43% 12%
Price/Free Cash Flow Ratio 26.03 14% 8%
Management Effectiveness  
Return on Equity 20.95% 79% 83%
Return on Invested Capital 15.04% 87% 78%
Return on Assets 7.85% 86% 87%
Debt to Equity Ratio 46.79% 50% 61%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.